TOKYO--(BUSINESS WIRE)--Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-63 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and children foods (under the age of three) on 25 July, 2024.

东京--（商业新闻短讯）--日本领先的乳制品公司森永乳业有限公司（东京：2264）今天宣布，其专有益生菌婴儿双歧杆菌M-63于2024年7月25日被中华人民共和国国家卫生委员会（NHC）批准为用于婴幼儿食品（3岁以下）的新食品成分。

This approval marks a significant milestone for the company, making it the only Japanese firm to have three bifidobacteria strains registered for use in China’s infant and toddler food market1..

这一批准标志着该公司的一个重要里程碑，使其成为唯一一家在中国婴幼儿食品市场注册使用三种双歧杆菌菌株的日本公司1。。

*1 Source: Public announcement published on the website of the China National Center for Food Safety Risk Assessment (August 5, 2024)

*1来源：中国国家食品安全风险评估中心网站发布的公告（2024年8月5日）

The newly registered Bifidobacterium infantis M-63 joins Morinaga Milk’s other approved strains, Bifidobacterium breve M-16V and Bifidobacterium longum BB536. All three strains are now permitted for use in foods for children under three years old in China, meeting the country's stringent nutritional and safety standards..

新注册的婴儿双歧杆菌M-63与Morinaga Milk的其他批准菌株短双歧杆菌M-16V和长双歧杆菌BB536合并。这三种菌株现在都被允许用于中国三岁以下儿童的食品中，符合国家严格的营养和安全标准。。

Expanding Global Presence

扩大全球影响力

This approval aligns with Morinaga Milk’s 10-year vision to become a globally recognized company with a significant international presence. As part of this vision, the company aims to achieve a Global Business sales ratio of 15% or more by the fiscal year ending in March 2029. The approval of Bifidobacterium infantis M-63 represents a strategic step towards this goal, allowing Morinaga Milk to strengthen its bacteria business in the Chinese market, which accounts for more than 40% of the global formula milk market and is the second-largest supplement market worldwide2..

这一批准符合森永乳业的10年愿景，即成为一家具有重要国际影响力的全球公认公司。。婴儿双歧杆菌M-63的批准代表着朝着这一目标迈出的战略一步，使森永乳业能够加强其在中国市场的细菌业务，中国市场占全球配方奶市场的40%以上，是全球第二大补充剂市场2。。

*2 Source: Survey by Euromonitor International (May 2024), based on retail sales prices

*2资料来源：欧睿国际（2024年5月）根据零售价格进行的调查

Health Benefits of Bifidobacterium infantis M-63

婴儿双歧杆菌M-63的健康益处

Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants.

婴儿双歧杆菌M-63是人类居住双歧杆菌（HRB）的独特益生菌菌株，双歧杆菌天然存在于人体肠道中，以其利用母乳中发现的母乳低聚糖（HMO）的能力而闻名，可显着改善健康足月婴儿的肠道环境。

With China's recent approval of HMO use in formula milk in October 20233, the combination of Bifidobacterium infantis M-63 and HMO is expected to support the growth of beneficial intestinal bacteria, enhancing the development and health of infants and toddlers4..

随着中国最近于20233年10月批准在配方奶中使用HMO，婴儿双歧杆菌M-63和HMO的组合有望支持有益肠道细菌的生长，促进婴幼儿的发育和健康4。。

*3 Source: National Health Commission of the People’s Republic of China, No. 8, 2023 (Sept. 22, 2023)

*3资料来源：中华人民共和国国家卫生委员会，2023年第8号（2023年9月22日）

*4 Source: Mintel, “HMOs approval in China infant formula is a game changer” (Jan. 2024)

*4资料来源：Mintel，“HMO在中国的批准婴儿配方奶粉改变了游戏规则”（2024年1月）

Probiotics strain of bifidobacteria registered as New Food Ingredients in China

双歧杆菌益生菌菌株在中国注册为新食品成分

Strain

应变

Registration date

注册日期

Bifidobacterium breve M-16V

短双歧杆菌M-16V

Registered name: 短双歧杆菌 M-16V

Registered name: 短双歧杆菌 M-16V

2016

2016

Bifidobacterium longum subsp. longum BB536

长双歧杆菌亚种。长BB536

Registered name: 长双歧杆菌长亚种 BB536

Registered name: 长双歧杆菌长亚种 BB536

2022

2022

Bifidobacterium longum subsp. infantis M-63

长双歧杆菌亚种。婴儿M-63

Registered name: 长双歧杆菌婴儿亚种M-63

Registered name: 长双歧杆菌婴儿亚种M-63

2024

2024

* All three strains are approved for use in foods for infants and toddlers under the age of three.

*这三种菌株都被批准用于三岁以下婴幼儿的食品中。

Commitment to Quality and Research

对质量和研究的承诺

Morinaga Milk has been at the forefront of bifidobacteria research since discovering Bifidobacterium longum BB536 in 1969. The company leads globally in the number of clinical research papers on bifidobacteria, underlining its commitment to advancing scientific understanding and improving public health..

自1969年发现长双歧杆菌BB536以来，森永牛奶一直处于双歧杆菌研究的前沿。该公司在双歧杆菌临床研究论文数量方面居全球领先地位，突显了其致力于促进科学理解和改善公共健康。。

Future Prospects

未来前景

The registration of Bifidobacterium infantis M-63 paves the way for its use in a wide range of products. Morinaga Milk plans to leverage this approval to expand collaborations with major formula milk manufacturers and promote supplements and other related products in China and globally. By providing accurate information on the benefits of Bifidobacterium infantis M-63 to consumers and partners, Morinaga Milk aims to enhance the health and nutrition of people worldwide..

婴儿双歧杆菌M-63的注册为其在多种产品中的应用铺平了道路。森永乳业计划利用这一批准扩大与主要配方奶制造商的合作，并在中国和全球推广补充剂和其他相关产品。通过向消费者和合作伙伴提供有关婴儿双歧杆菌M-63益处的准确信息，森永牛奶旨在增强全世界人民的健康和营养。。

About Morinaga Milk Industry

森永乳业简介

Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide.

森永乳业有限公司是日本领先的乳制品公司之一，在利用乳制品和功能性成分的营养特性方面拥有一个多世纪的历史。Morinaga Milk也是全球重要的益生菌制造商，擅长创新技术，并在全球范围内提供优质益生菌和功能性成分。

Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/..

自20世纪60年代以来，森永乳业一直致力于益生菌双歧杆菌的安全性，功能性健康益处和作用机制的研究，以更好地了解其在维持人类健康中的作用。有关森永人类住宅双歧杆菌（HRB）益生菌的更多信息，请访问我们https://morinagamilk-ingredients.com/..